Last $8.09 USD
Change Today -0.03 / -0.37%
Volume 17.3K
POZN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 10:11 AM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

pozen inc (POZN) Snapshot

Open
$8.14
Previous Close
$8.12
Day High
$8.14
Day Low
$8.07
52 Week High
04/25/14 - $9.73
52 Week Low
11/7/13 - $4.38
Market Cap
255.1M
Average Volume 10 Days
167.3K
EPS TTM
$-0.05
Shares Outstanding
31.5M
EX-Date
12/31/13
P/E TM
--
Dividend
--
Dividend Yield
21.55%
Current Stock Chart for POZEN INC (POZN)

Related News

No related news articles were found.

pozen inc (POZN) Related Businessweek News

No Related Businessweek News Found

pozen inc (POZN) Details

POZEN Inc., a pharmaceutical company, develops products for the treatment of acute and chronic pain, and pain related conditions in the United States and internationally. Its primary PA product candidates comprise PA32540 and PA8140 for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, which have completed clinical development in the United States. The company’s products also include Treximet for acute treatment of migraine attacks with or without aura in adults; and VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing non-steroidal anti-inflammatory drugs (NSAID)-associated gastric ulcers. It has collaborations with GlaxoSmithKline for the development and commercialization of proprietary combinations of a triptan and a long-acting NSAID; and Sanofi US for the commercialization of PA product candidates, as well as with AstraZeneca AB. The company was founded in 1996 and is headquartered in Chapel Hill, North Carolina.

16 Employees
Last Reported Date: 03/6/14
Founded in 1996

pozen inc (POZN) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $591.9K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $353.1K
Chief Medical Officer
Total Annual Compensation: $372.0K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $339.8K
Compensation as of Fiscal Year 2013.

pozen inc (POZN) Key Developments

POZEN Inc. Announces Unaudited Financial Results for the Second Quarter and Six Months Ended June 30, 2014

POZEN Inc. announced unaudited financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue of $7.4 million compared to $1.7 million in 2013. The company reported net income attributable common stockholders of $3.0 million, or $0.09 per diluted common share compared to net loss attributable common stockholders of $4.0 million, or $0.13 per diluted common share, for the second quarter of 2013. For the six months, total revenue of $15.0 million compared to $3.1 million in last year. The company reported net income attributable common stockholders of $5.9 million, or $0.18 per diluted common share compared to net loss attributable common stockholders of $9.8 million, or $0.32 per diluted common share, for the first half of 2013.

POZEN Seeks Acquisitions

POZEN Inc. (NasdaqGS:POZN) is seeking acquisitions. POZEN said, "Although not a primary component of our current strategy, the identification of new compounds or product candidates for development has led us in the past, and may continue to require us, to enter into license or other collaborative agreements with others, including pharmaceutical companies and research institutions. Such collaborative agreements for the acquisition of new compounds or product candidates would typically require us to pay license fees, make milestone payments and/or pay royalties."

POZEN Inc. to Report Q2, 2014 Results on Aug 07, 2014

POZEN Inc. announced that they will report Q2, 2014 results at 9:00 AM, Eastern Standard Time on Aug 07, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
POZN:US $8.09 USD -0.03

POZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,553 GBp +59.50
Endo International PLC $67.36 USD -0.89
GlaxoSmithKline PLC 1,440 GBp +6.00
Merck & Co Inc $60.07 USD +0.185
Sunesis Pharmaceuticals Inc $7.30 USD +0.06
View Industry Companies
 

Industry Analysis

POZN

Industry Average

Valuation POZN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.3x
Price/Book 8.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact POZEN INC, please visit www.pozen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.